Sevelamer Hydrochloride for Tumor Lysis Syndrome-related Hyperphosphatemia.

Abstract

BACKGROUND:

Tumour lysis syndrome is associated with high levels of uric acid, phosphate and potassium along with low levels of calcium and abnormal renal function. Sevelamer, an oral phosphate-binder is used in the treatment of hyperphosphatemia in children and adults on hemodialysis.

CASE CHARACTERISTICS:

Two children with T-cell acute lymphoblastic leukemia who presented with a high tumour load and developed tumour lysis syndrome.

OBSERVATION:

Both children received Rasburicase and Sevelamer hydrochloride. The serum phosphate reduced to normal levels within 24-48 hrs of initiation of sevelamer hydrochloride.

MESSAGE:

Sevelamer appears to be an effective treatment for hyperphosphatemia associated with tumour lysis syndrome.

• Authors: Harsha L Prasada
• Journal: Indian pediatrics (Indian Pediatr) Vol. 52 Issue 7 Pg. 613-5 (Jul 2015) ISSN: 0974-7559 [Electronic] India
• PMID: 26244958 (Publication Type: Case Reports, Journal Article)

Chemical References

• Phosphates
• Uric Acid
• Sevelamer

Topics

• Child
• Humans
• Hyperphosphatemia (blood, drug therapy, etiology)
• Male
• Phosphates (blood)
• Sevelamer (therapeutic use)
• Tumor Lysis Syndrome (blood, complications)
• Uric Acid (blood)